NL-OMON34305已完成3 期
The TEAM trial (Tasigna efficacy in advanced melanoma): A randomized, phase III, open label, multi-center, two-arm study to compare the efficacy of Tasigna® versus dacarbazine (DTIC) in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation - The TEAM trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Histologically confirmed mucosal, acral or cutaneous melanoma.
- •2. Presence of a c-Kit mutation of exon 11 or 13, or mutations Y822D and Y823D of exon 17, as confirmed by the central laboratory.
- •3. Stage III unresectable or stage IV disease.
- •4. The presence of one or more measurable lesions as detected by radiological or photographic methods and assessed according to RECIST.lesions must have a size of at least 10mm at longest diameter (using a slice thickness of 5 mm).
- •5. WHO performance status 0 - 2.
- •6. At least 28 days since major surgery and 7 days since skin/tumor biopsy until start of study drug.
- •7. Age 18 or greater.
- •8. Patients must have adequate bone marrow and organ function as defined by the following laboratory values:
- •* Biochemistry parameters within normal ranges prior to and at the latest by the day of first dosing, achieved by correction with supplements if necessary.
- •* ALT and AST * 2.5 x ULN (upper limit of normal) or * 5.0 x ULN if considered due to tumor.
- •* Alkaline phosphatase * 2.5 x ULN or * 5.0 x ULN if considered due to tumor.
- •* Serum bilirubin * 1.5 x ULN.
- •* Serum creatinine * 1.5 x ULN
- •* Serum amylase * 1.5 x ULN and serum lipase * 1.5 x ULN.
- •* Hemoglobin * 9.0 g/dL, absolute neutrophil count *1.5 x 109/L, platelets *100 x 109/L.
- •9. The capacity to understand the patient information sheet and the ability to provide written informed consent.
- •10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.
排除标准
- •1. C-Kit mutation of exons 17(except mutations Y822D or Y823D) or 18.
- •2. Patients with c-Kit amplifications only and no mutation.
- •3. Patients with any NRAS or BRAF mutation
- •4. Patients with known untreated or treated brain metastases as shown at the screening visit or earlier (metastatic disease M1a, M1b, M1c are allowed).
- •5. Patients who have had any prior treatment with TKIs or DTIC.
- •6. Patients receiving medications or herbal extracts which interfere with nilotinib metabolism which are not discontinued by the time of the baseline visit.
- •7. Impaired cardiac function, including any one of the following:
- •* LVEF < 45% or below institutional lower limit of the normal range (which ever is higher) as determined by MUGA scan or echocardiogram.
- •* Complete left bundle branch block.
- •* Use of a cardiac pacemaker.
- •* Congenital long QT syndrome.
- •* History of or presence of significant ventricular or atrial tachyarrhythmias.
- •* Clinically significant resting bradycardia (< 50 beats per minute).
- •* QTc > 450 msec on screening ECG (using the QTcF formula).
- •* Right bundle branch block plus left anterior hemiblock, bifascicular block.
- •* Myocardial infarction within 12 months prior to randomization.
- •* Unstable angina diagnosed or treated during the past 12 months.
- •* Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).
- •8. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of nilotinib (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or extensive gastric or small bowel resection).
- •9. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis.
- •10. Acute or chronic liver or renal disease considered unrelated to the tumor.
- •11. Other concurrent severe and/or uncontrolled medical conditions (e.g. uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.
- •12. Patients who are currently receiving treatment with any medications that have a significant potential to prolong the QT interval. See link for list of these medications: http://www.torsades.org/medical-pros/druglists/printable-drug-list.cfm.
- •13. Patients currently receiving therapy with strong CYP3A4 inhibitors. See link for list of these medications: http://medicine.iupui.edu/flockhart/table.htm.
- •14. Patients receiving therapy with strong CYP3A4 inducers. See link for list of these medications: http://medicine.iupui.edu/flockhart/table.htm.
- •15. Patients who have received cytotoxic chemotherapy * 4 weeks (6 weeks for nitrosurea or mitomycin-C) prior to starting study drug or who have not recovered from the side effects of such therapy.
- •16. Patients who have received immunotherapy * 1 week prior to starting study drug or who have not recovered from the side effects of such therapy.
- •17. Patients who have received any investigational drug * 4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy.
- •18. Patients who have received wide field radiotherapy * 4 weeks or limited field radiation for palliation * 2 weeks prior to starting study drug or who have not recovered from side effects of
研究者
相似试验
撤回
2 期
The TEAM trial (Tasigna efficacy in advanced melanoma): A phase II, open label, multi-center, single-arm study to assess the efficacy of Tasigna® in the treatment of patients with metastatic and/or inoperable melanoma harboring a c- Kit mutatiodisseminated skin cancermetastatic melanoma10040900NL-OMON37871ovartis3
进行中（未招募）
1 期
Tasigna efficacy in advanced melanomatreatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutationMedDRA version: 14.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015514-21-NLovartis Pharma Services AG55
进行中（未招募）
不适用
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A phase II, open label, multi-center, single-arm study to assess the efficacy of Tasigna ® in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation. - The TEAM-trialtreatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutationMedDRA version: 17.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2009-015514-21-SEovartis Pharma Services AG41
进行中（未招募）
不适用
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A randomized, phase III, open label, multi-center, two-arm study to compare the efficacy of Tasigna ® versusdacarbazine (DTIC) in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation.EUCTR2009-015514-21-BEovartis Pharma Services AG120
进行中（未招募）
不适用
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A phase II,open label, multi-center, single-arm study to assess the efficacy ofTasigna ® in the treatment of patients with metastatic and/orinoperable melanoma harboring a c-Kit mutation.EUCTR2009-015514-21-DEovartis Pharma Services AG41